DYNE THERAPEUTICS INC. - COMMON STOCK

Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026

10 Jan 2025 06:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

09 Jan 2025 07:30:04 By Nasdaq GlobeNewswire

Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET

08 Jan 2025 16:05:29 By Nasdaq GlobeNewswire

Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

12 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Upcoming Investor Conferences

07 Nov 2024 16:15:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases

09 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference

23 Sep 2024 08:56:28 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces Key Leadership Appointments

03 Sep 2024 06:31:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts

03 Sep 2024 06:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

29 Aug 2024 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

12 Aug 2024 17:10:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease

24 Jun 2024 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress

13 Jun 2024 16:40:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Jefferies Global Healthcare Conference

30 May 2024 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

28 May 2024 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock

21 May 2024 20:39:57 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

20 May 2024 16:01:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints

20 May 2024 06:30:06 By Nasdaq GlobeNewswire

Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET

19 May 2024 08:00:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

02 May 2024 16:10:00 By Nasdaq GlobeNewswire